• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Angiopoietin-like protein 2 and angiopoietin-like protein 6 levels in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者血清血管生成素样蛋白2和血管生成素样蛋白6水平的研究
Arch Med Sci. 2018 Jun;14(4):781-787. doi: 10.5114/aoms.2016.61811. Epub 2016 Aug 16.
2
Longitudinal Changes in Serum Levels of Angiopoietin-Like Protein 6 and Selenoprotein P After Gastric Bypass Surgery.胃旁路手术后血清血管生成素样蛋白6和硒蛋白P水平的纵向变化
Obes Surg. 2016 Apr;26(4):825-32. doi: 10.1007/s11695-015-1808-2.
3
Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis.肝脂肪变性患者血清血管生成素样肽 4 水平。
Cytokine. 2018 Nov;111:496-499. doi: 10.1016/j.cyto.2018.05.030. Epub 2018 Jun 14.
4
Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study.γ-谷氨酰转肽酶升高与非酒精性脂肪性肝病患者的代谢综合征、肝脂肪变性和纤维化相关:一项基于社区的横断面研究。
Kaohsiung J Med Sci. 2021 Sep;37(9):819-827. doi: 10.1002/kjm2.12395. Epub 2021 May 17.
5
The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.二甲双胍对非酒精性脂肪性肝病患者氨基转移酶水平、代谢参数和体重指数的影响:一项荟萃分析。
Curr Pharm Des. 2021;27(29):3235-3243. doi: 10.2174/1381612827666210315144821.
6
The association of angiopoietin-like peptide 4 levels with obesity and hepatosteatosis in adolescents.血管生成素样肽 4 水平与青少年肥胖和肝脂肪变性的相关性。
Cytokine. 2020 Jan;125:154802. doi: 10.1016/j.cyto.2019.154802. Epub 2019 Aug 13.
7
The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中丙氨酸氨基转移酶活性升高与代谢因素之间的关联。
Metabolism. 2006 Dec;55(12):1604-9. doi: 10.1016/j.metabol.2006.07.021.
8
Utility of MR proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents.超重青少年非酒精性脂肪肝中磁共振质子密度脂肪分数的效用及其与超声和生化标志物的相关性。
J Pediatr Endocrinol Metab. 2020 Apr 28;33(4):473-479. doi: 10.1515/jpem-2019-0463.
9
Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children.肥胖韩国儿童中胰岛素抵抗与作为非酒精性脂肪性肝病(NAFLD)替代指标的血清丙氨酸氨基转移酶之间的关系。
Diabetes Res Clin Pract. 2008 Sep;81(3):321-6. doi: 10.1016/j.diabres.2008.05.006. Epub 2008 Jun 20.
10
Influence of thyroid dysfunction on serum levels of angiopoietin-like protein 6.
Metabolism. 2015 Oct;64(10):1279-83. doi: 10.1016/j.metabol.2015.06.015. Epub 2015 Jun 24.

引用本文的文献

1
Circulating Angiopoietin-like Protein 6 Levels and Clinical Features in Patients with Type 2 Diabetes.2型糖尿病患者循环血管生成素样蛋白6水平与临床特征
Intern Med. 2025 Mar 1;64(5):643-649. doi: 10.2169/internalmedicine.3609-24. Epub 2024 Aug 8.
2
Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation.肝分泌因子:揭示肝组织与胰岛素抵抗和炎症相关的分子和细胞机制。
Acta Diabetol. 2024 Nov;61(11):1339-1361. doi: 10.1007/s00592-024-02335-9. Epub 2024 Jul 20.
3
From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病:土耳其非酒精性脂肪性肝病患者代谢特征及代谢功能障碍相关脂肪性肝病潜在风险的荟萃分析与系统评价
Hepatol Forum. 2024 Jul 2;5(3):126-138. doi: 10.14744/hf.2023.2023.0042. eCollection 2024.
4
Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss.肥胖受试者体重减轻后的成纤维细胞生长因子21水平及肝脏炎症生物标志物
Arch Med Sci. 2021 Mar 18;18(1):36-44. doi: 10.5114/aoms/98948. eCollection 2022.
5
Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease.多维度生物标志物分析,包括非酒精性脂肪性肝病的线粒体应激指标。
Gut Liver. 2022 Mar 15;16(2):171-189. doi: 10.5009/gnl210106.
6
Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.血管生成素样蛋白作为心血管疾病的治疗靶点:关注脂质紊乱。
Expert Opin Ther Targets. 2020 Jan;24(1):79-88. doi: 10.1080/14728222.2020.1707806. Epub 2020 Jan 15.

本文引用的文献

1
Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.中心性肥胖、2型糖尿病与胰岛素:探寻一条荆棘满途的通路。
Arch Med Sci. 2015 Jun 19;11(3):463-82. doi: 10.5114/aoms.2015.52350.
2
The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.非肥胖非糖尿病土耳其人群中胰岛素抵抗、代谢综合征与非酒精性脂肪性肝病之间的关系:一项初步研究。
Turk J Gastroenterol. 2014 Dec;25 Suppl 1:63-8. doi: 10.5152/tjg.2014.6233.
3
Relationship between serum levels of angiopoietin-related growth factor and metabolic risk factors.血清血管生成素相关生长因子水平与代谢危险因素之间的关系。
Horm Metab Res. 2014 Sep;46(10):685-90. doi: 10.1055/s-0034-1382078. Epub 2014 Jul 10.
4
Serum Angptl2 levels are independently associated with albuminuria in type 2 diabetes.血清 Angptl2 水平与 2 型糖尿病患者的蛋白尿独立相关。
Diabetes Res Clin Pract. 2013 Jun;100(3):385-90. doi: 10.1016/j.diabres.2013.03.028. Epub 2013 Apr 18.
5
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?非酒精性脂肪性肝病:一个新的重要心血管风险因素?
Eur Heart J. 2012 May;33(10):1190-200. doi: 10.1093/eurheartj/ehr453. Epub 2012 Mar 8.
6
Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults.超声检查发现的非酒精性脂肪肝是识别非肥胖、非糖尿病中年亚洲成年人胰岛素抵抗患者的独立预测因子。
Am J Gastroenterol. 2012 Apr;107(4):561-7. doi: 10.1038/ajg.2011.400. Epub 2011 Nov 22.
7
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.系统综述:非酒精性脂肪性肝病和非酒精性脂肪性肝炎的诊断和分期。
Aliment Pharmacol Ther. 2011 Mar;33(5):525-40. doi: 10.1111/j.1365-2036.2010.04556.x. Epub 2010 Dec 29.
8
Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases.血管生成素样蛋白:肥胖及相关代谢性疾病治疗的新兴靶点。
FEBS J. 2011 Feb;278(4):559-64. doi: 10.1111/j.1742-4658.2010.07979.x. Epub 2010 Dec 23.
9
Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance.血管生成素样蛋白2促进慢性脂肪组织炎症和肥胖相关的全身性胰岛素抵抗。
Cell Metab. 2009 Sep;10(3):178-88. doi: 10.1016/j.cmet.2009.08.003.
10
Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis.糖尿病和慢性血液透析患者血清血管生成素相关生长因子水平
Metabolism. 2009 Apr;58(4):547-51. doi: 10.1016/j.metabol.2008.11.016.

非酒精性脂肪性肝病患者血清血管生成素样蛋白2和血管生成素样蛋白6水平的研究

Angiopoietin-like protein 2 and angiopoietin-like protein 6 levels in patients with nonalcoholic fatty liver disease.

作者信息

Erkan Gulbanu, Muratoglu Suzan, Ercin Ugur, Bilgihan Ayse

机构信息

Department of Internal Medicine, Division of Gastroenterology, Istanbul Medipol University, Istanbul, Turkey.

Department of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey.

出版信息

Arch Med Sci. 2018 Jun;14(4):781-787. doi: 10.5114/aoms.2016.61811. Epub 2016 Aug 16.

DOI:10.5114/aoms.2016.61811
PMID:30002695
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6040129/
Abstract

INTRODUCTION

The aim of the current study was to examine the difference between patients detected with nonalcoholic fatty liver disease (NAFLD) and healthy subjects in terms of serum angiopoietin-like protein (ANGPTL) 2 and ANGPTL6 levels and to evaluate the correlation between ANGPTL2 and ANGPTL6 levels and liver enzyme levels, fasting glucose, lipid levels, and steatosis degree on ultrasonography (USG).

MATERIAL AND METHODS

A total of 159 participants were included in the study. The participants were divided into 3 groups depending on the steatosis degree on USG and serum alanine aminotransferase (ALT) levels: the NAFLD group with increased ALT, the NAFLD group with normal ALT, and the healthy control group. The groups were compared in terms of biochemical and ultrasonographic findings, insulin resistance, metabolic syndrome (MetS), and anthropometric parameters.

RESULTS

There was no significant difference between NAFLD patients and healthy subjects with respect to serum ANGPTL2 and ANGPTL6 levels ( > 0.05). ANGPTL2 levels did not correlate with serum, biochemical, or ultrasonographic findings, or anthropometric parameters ( > 0.05). A positive correlation was found between serum ANGPTL6 levels and fasting blood glucose, ALT, alkaline phosphatase, γ-glutamyl transpeptidase, fasting insulin, and HOMA-IR levels.

CONCLUSIONS

While our findings suggest no relationship between serum ANGPTL2 and ANGPTL6 levels and NAFLD, ANGPTL6 levels may be related to metabolic and biochemical parameters. The effects of ANGPTL2 and ANGPTL6 in the pathogenesis of NAFLD should be investigated further.

摘要

引言

本研究的目的是检测非酒精性脂肪性肝病(NAFLD)患者与健康受试者血清血管生成素样蛋白(ANGPTL)2和ANGPTL6水平的差异,并评估ANGPTL2和ANGPTL6水平与肝酶水平、空腹血糖、血脂水平以及超声检查(USG)下脂肪变性程度之间的相关性。

材料与方法

本研究共纳入159名参与者。根据USG下的脂肪变性程度和血清丙氨酸氨基转移酶(ALT)水平将参与者分为3组:ALT升高的NAFLD组、ALT正常的NAFLD组和健康对照组。比较各组的生化和超声检查结果、胰岛素抵抗、代谢综合征(MetS)和人体测量参数。

结果

NAFLD患者与健康受试者的血清ANGPTL2和ANGPTL6水平无显著差异(>0.05)。ANGPTL2水平与血清、生化或超声检查结果以及人体测量参数均无相关性(>0.05)。血清ANGPTL6水平与空腹血糖、ALT、碱性磷酸酶、γ-谷氨酰转肽酶、空腹胰岛素和HOMA-IR水平呈正相关。

结论

虽然我们的研究结果表明血清ANGPTL2和ANGPTL6水平与NAFLD之间无关联,但ANGPTL6水平可能与代谢和生化参数有关。ANGPTL2和ANGPTL6在NAFLD发病机制中的作用应进一步研究。